Study Design. The aim of this study is to test the effect of cartilage oligomeric matrix protein (COMP) on enhancing rhBMP-2 induced spinal fusion in a prospective 8-week interventional trial of spinal fusion in rats. Objective. To determine whether the amount of bone morphogenetic protein-2 (BMP-2) required to achieve spinal fusion in a pre-clinical model can be reduced by the addition of COMP. Summary of Background Data. BMPs are applied clinically at supraphysiological doses to promote spinal fusion by inducing osseous growth, but dose-related limitations include ectopic bone formation and local inflammatory reactions. COMP is a matricellular BMP-binding protein expressed during endochondral ossification and fracture healing. In vitro studies demonstrate enhanced activity of BMP bound to COMP. We hypothesized that BMP bound to COMP could achieve equivalent spinal fusion rates at lower doses and with fewer complications. Methods. Posterolateral intertransverse process spinal fusion at L4 to L5 was performed in 36 Lewis rats. COMP (10 mg) was tested with or without ''low-dose'' rhBMP-2 (2 mg), and the results were compared with the ''low-dose'' (2 mg rhBMP-2) and ''high-dose'' (10 mg rhBMP-2) groups. All groups utilized insoluble collagen bone matrix carrier (ICBM). Fusion was evaluated by radiology, histology, and manual palpation. BMP release kinetics were evaluated in vitro.
S
pinal fusion is a widely accepted procedure first described by Hibbs 1 and Albee 2 in 1911. Between 1998 and 2008, the annual number of spinal fusion discharges in the United States has increased 2.4-fold (137%) from 174,223 to 413,171 and the national bill for spinal fusion increased 7.9-fold. 3 However, one significant complication in spinal fusions are nonunions (pseudoarthroses), 4 which may account for up to 23% of revision lumbar spinal surgeries. 5 Surgical strategies to minimize the incidence of nonunion include instrumentation and improved bioactivity of the graft material. Iliac crest bone graft (ICBG) represents the gold standard for graft material but is limited by both harvesting morbidity and availability. 6 Osteobiologics such as bone morphogenetic protein-2 (BMP-2) can be superior to ICBG in achieving spinal From the and in fact, the FDA issued a 2008 public health notification concerning life-threatening complications associated with ''off-label'' BMP use in cervical spine fusion. 12 Although some of these complications may not be solely attributed to the off-label use of BMP, [13] [14] [15] there is a clinical need to minimize the large doses of BMPs and expand its use in spinal fusion surgeries.
In a clinical setting, purified rhBMP-2 (INFUSE; Medtronic, Memphis, TN) is reconstituted with sterile water and placed on an absorbable carrier (bovine collagen sponge) that is then applied into the surgical site. Thus, the BMP is presented in the surgical site primarily as a soluble growth factor, and supraphysiological doses of 3.5 to 20 mg per fusion level are commonly applied to induce adequate bone formation. 16 This is in stark contrast to endogenous BMPs, which are present in very low amounts (2-30 mg per kilogram bone 17, 18 ) and tightly bound to instructive matrix molecules that help limit their bioavailability and direct appropriate cellular responses. Perhaps by more closely mimicking the biological context surrounding endogenous BMPs, we can lower the adverse effects of recombinant BMPs, reduce the dose necessary for achieving spinal fusion, and possibly also lower costs associated with high doses of recombinant human proteins.
Matricellular proteins have a modular composition and function by concurrently binding to structural proteins in the matrix, cell surface receptors, remodeling proteinases, and cytokines. 19, 20 Cartilage oligomeric matrix protein (COMP) is a matricellular protein involved in the assembly of collagen fibrils and other structural matrix components. COMP interacts with structural matrix components, including collagens and proteoglycans, cell surface receptors such as integrins and CD47, remodeling proteinases such as Matrix Metallo Proteinases and A Disintegrin And Metalloprotease with ThromboSpondin motifs, and growth factors, including Transforming Growth Factor-beta 21 and BMPs (reviewed in the study by Acharya et al 22 ) . COMP is expressed by hypertrophic chondrocytes and osteoblasts during endochondral ossification, 23 and its expression is increased during fracture healing. 24 Recent work from our group demonstrated that COMP binds to BMP-2, and such binding increases the osteogenic activity of BMP-2 both in vitro and in an ectopic bone formation assay in vivo. 25 On the basis of this evidence, our hypothesis is that BMPs bound to COMP will better approximate the biological context of endogenous BMPs to more efficiently direct cellular differentiation toward osteogenesis. The goal of this study is to determine whether COMP, together with BMP-2, will reduce the dose of BMP-2 required for spinal fusion in a clinically relevant rat model.
MATERIALS AND METHODS

Implant Preparation
Recombinant human COMP was prepared from stably transduced 293 T cells as described previously. 21, 26 Inactive collagenous demineralized bone matrix (ICBM) was kindly provided by Dr. A. Hari Reddi.
27,28 ICBM alone is unable to induce endochondral bone differentiation in the absence of additional growth factors 29 and was used as a substratum in every group. Recombinant human BMP-2 was purchased in the form of INFUSE Bone Graft (Medtronic, Memphis, TN). Infuse is not labeled for the use under discussion. BMP-2 and COMP were diluted with Phosphate Buffered Saline (PBS) to a final volume of 200 mL. The negative control group was composed of 200 mL PBS. The growth factor solutions were pipetted onto 25 mg of ICBM, allowed to bind 30 minutes, snap-frozen in liquid nitrogen, and lyophilized overnight.
Treatment groups differed only by the materials added to the ICBM carrier (Table 1 ). These doses are based on previous experience in our group suggesting that the 10 mg BMP-2 leads to near 100% fusion, while the 2 mg BMP induces new bone but consistently incomplete fusion.
Surgical Procedure
Animal protocols were approved by the UC Davis Animal Use and Care Advisory Committee, and surgeries were performed according to the UC Davis IACUC policy on survival surgery and all National Institutes of Health animal handling protocols. Thirty-six male Lewis rats (10-12 weeks old) were randomly divided into five subgroups. A posterior midline incision was made from L4-L7. Fascial incisions were made 2 to 3 cm on each side of the midline, and the transverse process of L4 to L5 and the 
BMP indicates bone morphogenetic protein; COMP, cartilage oligomeric matrix protein; ICBM, insoluble collagen bone matrix carrier.
intertransverse membrane were exposed. The dorsal aspects of L4 to L5 transverse processes were decorticated using a high-speed burr. Grafts were placed bilaterally in the paraspinal muscle bed, between and touching the transverse processes of L4 and L5. The rats were managed with subcutaneous injections of buprenorphine (0.05 mg/kg) for the control of perioperative and postoperative pain, and allowed to eat and drink ad libitum.
Graft Harvest and Manual Palpation
Eight weeks postsurgery, rats were euthanized by carbon dioxide inhalation and their lumbar spines were harvested whole. Spines were visually examined and manually palpated to assess the mechanical integrity of the fusion qualitatively. The extent of fusion was graded by three orthopedic surgeons according to the following scale: Grade 0, no fusion; Grade 1, partial fusion; Grade 2, complete fusion.
Micro-CT Analysis
After dissection, the spine tissue was fixed in 10% neutralbuffered formalin for five days and stored in 70% ethanol. Spines were scanned using micro-computed tomography (microCT; ScanCo mCT 35, Bassersdorf, Switzerland), with imaging settings according to the guidelines for analysis of rodent bone structure, at a resolution of 37 mm in all dimensions, with 55 kVp, 145 mAmp, and three averages of 300 ms integration time. 30 The extent of spinal fusion was assessed from dorsal and ventral view 3D renderings for each rat by three blinded graders using the following scale: Grade 0, no bone present between the transverse processes bilaterally; Grade 1, bone mass on one side only; Grade 2, bone mass bilaterally with lucency bilaterally; Grade 3, bone mass bilaterally with lucency on one side only; Grade 4, bridging bone with no gaps or lucent lines bilaterally.
Quantitative parameters were evaluated from the microCT by creating a region of interest (ROI) contoured to L4 and L5 transverse processes on left and right sides separately. Bone volume (BV), BV fraction (BVF), and tissue mineral density (TMD) were calculated in software (ScanCo). BV is a measure of total volume of mineralized tissue in the ROI (''mineralized'' defined as density >375 mgHA/cc). BVF is the ratio of BV to the total volume of the ROI. TMD is the mean density of the mineralized tissue.
Radiographic Assessment of Fusion
Fusion was assessed every other week using posteroanterior radiographs, which were graded by three trained blinded observers using the following scale: Grade 0, no bone present between the transverse processes bilaterally; Grade 1, minimal fusion; Grade 2, unilateral fusion; Grade 3, bilateral fusion.
Histology
After microCT analysis, samples were decalcified with 10% formic acid in citrate, and processed for standard paraffin embedding. Serial sagittal sections were cut from the center of the fusion mass (4-mm thick slices). The sectioned tissues were stained sequentially with hematoxylin and eosin (H&E) and evaluated for endochondral ossification. Photomicrographs were acquired using a Leica model EZ4D stereomicroscope Leico Microsystems GmbH, Wetzlar Germany, and multiple images assembled using the Photomerge function of Adobe Photoshop CS5.5.
BMP Release Kinetics From COMP/ICBM
BMP-2 (2 or 10 mg per tube) in the presence or absence of COMP was added to ICBM as described above and lyophilized overnight (n ¼ 3 per condition). The lyophilized product was suspended in 1 mL PBS and maintained at 378C. The entire volume of PBS was collected and refreshed at designated time points over 21 days and frozen until analysis. The release of BMP-2 was quantified using a human protein specific ELISA kit (R&D Systems, Minneapolis, MN) per manufacturer's instructions. Data were normalized to the total amount of BMP-2 released over the 3-week study duration for each condition.
Statistical Analysis
CT and palpation grades were compared between groups using Welch analysis of variance (ANOVA), which allows for unequal variances, followed by Games-Howell post hoc testing. Quantitative CT parameters were compared using an ANOVA with fixed effects for group, side (left and right), and a random effect for rat. X-ray data were analyzed using a longitudinal model, including fixed effects for group, time, and their interaction and a random effect for rat. Tukey pairwise comparisons of groups at each timepoint were conducted as contrasts within this model. Statistical analyses were conducted using the statistical software environment R, version 3.1.0 (R Core Team, 2014). Longitudinal modeling was conducted using the R package nlme, version 3.1-117. 31 Significance was set at P < 0.05.
RESULTS
Of the 36 rats in the study, 34 were included for the data analysis, and two rats were excluded because fusion occurred at different levels. All rats survived the surgical procedure with no wound complications, abnormal behavior, or deaths noted. There were no obvious adverse reactions to COMP. None of the rats showed any neurologic deficits before or after the surgical procedure, or during the 8-week follow-up period. The extent of spinal fusion was most accurately determined from high-resolution three-dimensional microCT reconstructions, and graded as shown in Figure 1 . Essentially complete fusion was observed in the HiBMP group, in agreement with our previous experience using this dose of BMP2 in spinal fusion. The low dose of BMP induced limited new bone formation and resulted in partial fusion in all animals. COMP significantly enhanced the extent of fusion induced by LoBMP, to the same extent seen in the positive control group (Figure 2A) . No bone formation was observed in the ICBM or COMP groups. These observations suggest that COMP can augment the activity of BMP to enhance spinal fusion, but COMP alone does not induce bone formation.
To assess the mechanical integrity of the spinal fusions semi-quantitatively, the dissected spines were palpated manually. The results confirm that the positive control (HiBMP) and the experimental group (LoBMPþCOMP) had a similar extent of bone formation and resistance to bending articulation, which was greater than that observed in the LoBMP and COMP groups ( Figure 2B) .
To assess the rate of fusion over time, biweekly radiographs were graded. Bone growth progressed to near complete fusion in the HiBMP and LoBMPþCOMP groups (Figure 3 ). The differences between these groups were not significant at any time point. LoBMP induced bone formation but incomplete fusion, and the extent of fusion in this group was statistically less than the HiBMP and LoBMPþCOMP groups at weeks 4 and later. COMP alone had an insignificant effect on spinal fusion. These results confirm the microCT data that COMP reduces the amount of BMP required to induce spinal fusion at 8 weeks, with the added insight that fusion progresses on a similar time scale as the HiBMP group.
In addition to determining the extent of fusion between adjacent vertebrae, we also examined the quality of the newly formed bone from the microCT scans ( Figure 4 ) and by histology ( Figure 5 ). The quantitative measure of BV showed that HiBMP and LoBMP were significantly higher than COMP alone (Figure 4 ). There was a trend (P < 0.10) that the BV was less in COMPþLoBMP than either HiBMP or LoBMP. The TMD was less in the COMPþLoBMP group than in the COMP or HiBMP group. There was no difference in BVF between any of the groups with BMP, and differences in TMD did not reach statistical significance (Figure 4) .
Finally, we examined whether COMP affects the in vitro release kinetics of BMP-2 from ICBM to provide insight into the causes of difference in bone formation. On the basis of total eluted mass, BMP-2 was released much faster when complexed with COMP than when directly adsorbed to ICBM ( Figure 6 ). As expected, initial loading of ICBM with more BMP-2 yielded an increase in the total amount of BMP-2 released. As a percentage of total initial dose, we observed similar relative mass of BMP-2 released from ICBM when complexed with COMP (7% of 2 mg BMP, 11% of 10 mg BMP). However, the adsorption of free BMP to ICBM resulted in large differences in total BMP released as a function of initial loading dose (0.4% of 2 mg, 18% of 10 mg) under the conditions studied.
DISCUSSION
Bone formation in spinal fusion involves a coordinated interplay between an osteoconductive scaffold, osteoprogenitor cells, and growth factors such as BMPs. The objectives of this study were to determine whether providing a more biologically relevant context for exogenous BMP-2, by binding it to the matricellular protein COMP, would result in a higher biological activity of BMP-2 and reduce the dose required for spinal fusion in a rat model. The results demonstrate that this approach was successful. In the presence of COMP, the delivery of 2 mg BMP-2 achieved a similar outcome to 10 mg of BMP-2 alone.
The clinical success of rhBMP-2 in anterior spinal fusion 32 has increased its off-label use, but with significant complications 11, 33, 34 and culminating in a series of articles calling for further research to evaluate the early-and longterm complications. 33, 35 The doses of BMP-2 (2.5-20 mg) used for adult spinal deformity are high compared with the BMP amounts in endogenous bone (2-30 mg/kg bone), 17, 18, 36, 37 which may contribute to the complications. Several approaches are being tested to minimize complications by lowering doses of BMP-2 while still maintaining its effectiveness. One approach mixes BMP-2 with additional growth factors, for example, NEL-like molecule-1 (Nell-1) has been successful in pre-clinical studies. [38] [39] [40] A second approach increases the in vivo half-life and local retention of BMP-2 using ''slow-release'' agents such as synthetic BMP-binding peptide [41] [42] [43] or creating a synthetic fusion protein of rhBMP-2 with a collagen-binding domain. 44 However, using heparin-conjugated fibrin as a slow-release delivery vehicle was not successful at reducing the BMP dose. 45 A third approach is the addition of bulking agents, such as biphasic calcium phosphate ceramic/collagen compression resistant matrix to BMP. [46] [47] [48] Similarly, bone marrow aspirate can improve the activity of low-dose BMPs. 49 Mixed results were obtained by reducing endogenous BMP antagonists using noggin siRNA delivered at the site of spinal fusion. 50 Many of these studies provide BMP as an unbound growth factor, a context that does not occur naturally. Our approach was to more closely mimic the biological context surrounding endogenous BMPs, by providing the growth factor pre-bound to an instructive matrix molecule (COMP). Although we do not expect COMP to directly modify osteogenic gene expression, we hypothesized that COMP affects BMP bioavailability and directs the appropriate cellular responses. We observed that although COMP itself did not induce bone formation, adding COMP to 2 mg BMP2 increased the fusion rate statistically similar to that of the 10 mg BMP2 group. The results of manual palpation and microCT correlated well with radiographic outcomes at the conclusion of the study, and histological analysis at 8 weeks showed normal new bone formation.
The quality of bone within a region-of-interest (ROI) drawn between adjacent vertebrae was semi-quantitatively assessed by microCT, with the unexpected observation of somewhat lower BV and TMD in the COMPþLoBMP group than the HiBMP group. We were unable to consistently differentiate new bone from old bone, thus the ROI includes a combination of both. Therefore, the BV and TMD measurements reflect a combination of the bone quality in both native and newly formed bone, and are affected by the amount of new bone growth between processes. Although this limitation may help explain the unexpected observations, these assays of bone quality are independent of the successful fusion of adjacent vertebrae.
The in vitro elution kinetics were compared between BMP-2 loaded directly on ICBM versus BMP-2þCOMP on ICBM. COMP increased the elution kinetics of BMP-2, with a much greater percentage released during the first few days. BMP-2 was completely eluted by day 10 in the COMP groups, while it continued to elute from the ICBM groups. At the lower concentration, COMP greatly enhances the total amount of BMP-2 recovered. In all cases, the majority of BMP-2 was not recovered from the ICBM. It is unknown whether the BMP-2 remained on the ICBM, or was denatured to the extent that it could not be detected by the ELISA assay employed to quantify the BMP-2. One limitation of the ELISA assay is that it is insensitive to the biological activity of the BMP. Differences in elution may be related to growth factor binding to the substrate. It is likely that BMP binds more effectively to ICBM than the BMP/COMP complex, resulting in differences in adsorption and desorption kinetics from the matrix. On the basis of the promising results in this preclinical model, we intend to examine these differences as the subject of future work.
CONCLUSION
Taken together, these data indicate that COMP enhances that biological activity of BMP and achieves statistically improved rates of fusion in this animal model of posterolateral spinal 
